Skip to main content

Advertisement

SpringerLink
Log in

Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study

  • ASTHMA
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Benralizumab and mepolizumab are new therapies for severe eosinophilic asthma. They are both humanized IgG antibodies, targeting the IL‐5 receptor and IL‐5, respectively, suppressing the corresponding pathways. No specific biomarkers have been proposed to evaluate treatment response to benralizumab or mepolizumab. The aim of this proteomic study was to compare serum protein profiles of patients with severe eosinophilic asthma before and after anti‐IL5 or anti‐IL5R therapies. Proteomic analysis highlighted 22 differently abundant spots. Among the proteins identified, CAYP1, A1AT and A2M expression was significantly modified in both groups of patients after therapies while ceruloplasmin showed a significant modification in the group of benralizumab treatment. These differentially expressed proteins could be potential biomarkers of response to mepolizumab and benralizumab treatments and need further evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Caruso M, Morjaria J, Emma R et al (2018) Biologic agents for severe asthma patients: clinical perspectives and implications. Intern Emerg Med 13:155–176. https://doi.org/10.1007/s11739-017-1773-y

    Article  PubMed  Google Scholar 

  2. Ghazi A, Trikha A, Calhoun WJ (2012) Benralizumab—a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity—a novel approach for the treatment of asthma. Expert Opin Biol Ther 12:113–118. https://doi.org/10.1517/14712598.2012.642359

    Article  CAS  PubMed  Google Scholar 

  3. Laviolette M, Gossage DL, Gauvreau G et al (2013) Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132:1086–1096.e5. https://doi.org/10.1016/j.jaci.2013.05.020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ortega HG, Liu MC, Pavord ID et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198–1207. https://doi.org/10.1056/NEJMoa1403290

    Article  CAS  PubMed  Google Scholar 

  5. FitzGerald JM, Bleecker ER, Nair P et al (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl 388:2128–2141. https://doi.org/10.1016/S0140-6736(16)31322-8

    Article  CAS  Google Scholar 

  6. Bianchi L, Gagliardi A, Campanella G et al (2013) A methodological and functional proteomic approach of human follicular fluid en route for oocyte quality evaluation. J Proteomics 90:61–76. https://doi.org/10.1016/j.jprot.2013.02.025

    Article  CAS  PubMed  Google Scholar 

  7. Cameli P, Bergantini L, d’Alessandro M et al (2020) A comprehensive evaluation of mepolizumab effectiveness in a real-life setting. Int Arch Allergy Immunol. https://doi.org/10.1159/000507996

    Article  PubMed  Google Scholar 

  8. Bargagli E, Cameli P, Carleo A et al (2019) The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases. Panminerva Med. https://doi.org/10.23736/S0031-0808.19.03754-6

    Article  PubMed  Google Scholar 

  9. Bruno A, Pace E, Chanez P et al (2009) Leptin and leptin receptor expression in asthma. J Allergy Clin Immunol 124(230–7):237.e1–4. https://doi.org/10.1016/j.jaci.2009.04.032

    Article  CAS  Google Scholar 

  10. Goldstein IM, Kaplan HB, Edelson HS, Weissmann G (1979) Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem 254:4040–4045

    CAS  PubMed  Google Scholar 

  11. Cameli P, Carleo A, Bergantini L et al (2020) Oxidant/antioxidant disequilibrium in idiopathic pulmonary fibrosis pathogenesis. Inflammation 43:1–7. https://doi.org/10.1007/s10753-019-01059-1

    Article  CAS  PubMed  Google Scholar 

  12. Sokolov AV, Kostevich VA, Zakharova ET et al (2015) Interaction of ceruloplasmin with eosinophil peroxidase as compared to its interplay with myeloperoxidase: reciprocal effect on enzymatic properties. Free Radic Res 49:800–811. https://doi.org/10.3109/10715762.2015.1005615

    Article  CAS  PubMed  Google Scholar 

  13. Provotorov VM, Budnevsky AV, Filatova YI (2016) Clinical manifestations of asthma during combination therapy using ceruloplasmin. Ter Arkh 88:36–39. https://doi.org/10.17116/terarkh201688336-39

    Article  CAS  PubMed  Google Scholar 

  14. Bergantini L, Cameli P, d’Alessandro M et al (2020) Regulatory T cells in severe persistent asthma in the era of monoclonal antibodies target therapies. Inflammation 43:393–400. https://doi.org/10.1007/s10753-019-01157-0

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

There is no support in the form of grant, gift, equipment, and/or drugs.

Author information

Author notes

  1. Lorenza Vantaggiato and Marco Perruzza should be regarded as joint first authors.

Authors and Affiliations

  1. Functional Proteomics Lab, Department of Life Sciences, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy

    Lorenza Vantaggiato, Luca Bini & Claudia Landi

  2. UOC Respiratory Diseases and Lung Transplantation, Department Internal and Specialist Medicine, University of Siena, Siena, Italy

    Marco Perruzza, Rosa Metella Refini, Laura Bergantini, Miriana d’Alessandro, Paolo Cameli, Elena Bargagli & Claudia Landi

  3. Unit of Basic and Applied Biosciences, University of Teramo, Via Balzarini 1, 64100, Teramo, Italy

    Davide Perruzza

Authors
  1. Lorenza Vantaggiato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Perruzza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosa Metella Refini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laura Bergantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Miriana d’Alessandro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paolo Cameli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Davide Perruzza
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luca Bini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elena Bargagli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Claudia Landi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CL, EB: Conceived and designed the project; CL, LB: designed experiments; LV, Md: performed experiments; LV, Md: sera preparation; LV, MP, L. Bini, ES: analyzed data; MP, PC: clinical data; CL, EB, DP: wrote manuscript; CL, RMR, L. Bini, EB: critical review; All Authors approval of the manuscript.

Corresponding author

Correspondence to Claudia Landi.

Ethics declarations

Conflict of interest

All the authors declare there is no conflict of interest related to this topic.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 15 kb)

Supplementary file2 (XLSX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vantaggiato, L., Perruzza, M., Refini, R.M. et al. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study. Lung 198, 761–765 (2020). https://doi.org/10.1007/s00408-020-00379-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-020-00379-6

Keywords

Search

Navigation